Recovering from a particularly rough patch, the drug industry is in the midst of a revolution. Doing away with the all-in-one, large-pharma blockbuster model, and welcoming the niftier open innovation structure, scavenging old actives or value-adding existing products remains the new normal to tide over this landmark period. Continual focus on formulation and delivery technologies to enable this transition encourages a flourish of technology developers. However, increasingly stiff competition reveals those with the X-factor for specific applications to those who are undifferentiated. Using the Lux Innovation Grid, this report segregates these developers for easier digestion.